Renewed hope in a once-abandoned cancer drug class

Could drugs that block the body's system for repairing damage to the genetic material DNA become a boon to health? As unlikely as it may seem, those compounds are sparking optimism as potential treatments for ovarian and breast cancers driven by a mutation in BRCA, a gene that made headlines when actress Angelina Jolie revealed she carries the mutation. The compounds, termed PARP inhibitors, are the topic of the cover story in the current edition of Chemical & Engineering News. C&EN is the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

Lisa Jarvis, C&EN senior editor, explains that some members of the family of enzymes known as PARP, which stands for poly(ADP-ribose) polymerase, help fix damaged DNA. When DNA is broken, PARP moves in and signals other enzymes to repair the break so the cell can live. As early as the 1980s, scientists looked seriously at stopping PARP from working in cancer cells. If they could damage cancer cells' DNA with chemotherapy and then block PARP from fixing it, the cancer cells would die. By the 2000s, scientists identified BRCA-positive cancer patients, whose cells' ability to repair double-stranded damage is already compromised, as good candidates for treatment with PARP inhibitors.

The story describes how PARP inhibitors held great promise. But a couple of years ago, momentum came to a screeching halt when one candidate, which had advanced to a Phase III clinical trial, failed to prolong patients' survival. More recently, researchers realized that the drug was not a PARP inhibitor. Soon after, an in-depth look at a previous study showed that a different drug candidate did in fact help some ovarian cancer patients. The findings breathed new life into PARP inhibitor research. Now, four drug candidates in this family are ready to enter Phase III clinical studies for breast and ovarian cancer.

More information: Pushing Cancer over the Edge, Chemical & Engineering News. cen.acs.org/articles/91/i24/Pu… ancer-Over-Edge.html

add to favorites email to friend print save as pdf

Related Stories

New mechanism of action for PARP inhibitors discovered

Nov 09, 2012

New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has led ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.